Northwest Biotherapeutics, founded in the United States, is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products to treat cancer. Their core mission is to harness the power of the immune system to combat cancer effectively. The company's flagship product platform, DCVax®, includes variants such as DCVax®-L, DCVax®-Direct, and DCVax®-Prostate, which utilize activated dendritic cells to generate and enhance immune responses against cancer. Northwest Biotherapeutics primarily targets the oncology market.

Key figures affiliated with Northwest Biotherapeutics include seasoned business executives and investors who have been appointed to its Board of Directors. The company has achieved notable milestones such as securing exclusive in-licenses for a portfolio of dendritic cell technology and intellectual property. Through its innovative approach to cancer treatment, Northwest Biotherapeutics has made significant strides in the biotechnology sector, contributing to advancements in cancer immunotherapy and offering new hope for patients battling the disease.